Durable brain response with pulse-dose crizotinib and ceritinib in ALK-positive non-small cell lung cancer compared with brain radiotherapy
详细信息 查看全文
- 作者：Elizabeth Dudnika ; Tali Siegalb ; c ; Leor Zachc ; d ; Aaron M. Allena ; c ; Dov Flexa ; c ; Shlomit Yust-Katzb ; c ; Dror Limonb ; Fred R. Hirsche ; Nir Peleda ; c ; nirp@post.tau.ac.il" class="auth_mail" title="E-mail the corresponding author
- 关键词：ALK rearrangement ; Brain metastases ; Ceritinib ; Crizotinib ; NSCLC
- 刊名：Journal of Clinical Neuroscience
- 出版年：2016
- 出版时间：April 2016
- 年：2016
- 卷：26
- 期：Complete
- 页码：46-49
- 全文大小：545 K
文摘
- •
Brain failure occurs in 50% of crizotinib-treated ALK+ NSCLC patients.
- •
Brain irradiation, the standard treatment, results in neurocognitive impairment.
- •
Pulse-dose crizotinib followed by ceritinib may provide a durable CNS control.
- •
This strategy may allow brain radiotherapy to be deferred.